Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

46.88
-1.4800-3.06%
Post-market: 46.880.00000.00%16:09 EDT
Volume:1.05M
Turnover:49.59M
Market Cap:2.88B
PE:11.08
High:48.68
Open:47.99
Low:46.54
Close:48.36
Loading ...

Protagonist Therapeutics Shares up 3% After Co Reports Higher Q4 Profit

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

Zacks
·
21 Feb

Protagonist Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
21 Feb

Protagonist Therapeutics' Q4 Earnings, License and Collaboration Revenue Rise

MT Newswires Live
·
21 Feb

Protagonist Therapeutics Shares up 3.9% Premarket After Co Reports Higher Q4 Profit

THOMSON REUTERS
·
21 Feb

Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M

MT Newswires Live
·
21 Feb

Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98

MT Newswires Live
·
21 Feb

Protagonist Therapeutics Inc: Qtrly License and Collaboration Revenue $ 170.6 Mln

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics Q4 Basic EPS USD 2.11

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics Q4 Net Income USD 131.674 Million VS. Ibes Estimate USD 22.5 Million

THOMSON REUTERS
·
21 Feb

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ACCESS Newswire
·
21 Feb

JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
19 Feb

Will Weakness in Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock Prove Temporary Given Strong Fundamentals?

Simply Wall St.
·
14 Feb

Protagonist Therapeutics participates in a conference call with Truist

TIPRANKS
·
08 Feb

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Feb

Protagonist Therapeutics (PTGX) Receives a Buy from Truist Financial

TIPRANKS
·
07 Feb